Skip to main content
Premium Trial:

Request an Annual Quote

Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study

NEW YORK – Personalis said today that it will employ its ImmunoID NeXT platform in an ovarian cancer study spearheaded by the University of New Mexico Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care.

The effort, being conducted at several centers across the US, will employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response to a combination of AstraZeneca's olaparib (Lynparza) and tremelimumab in women with recurrent BRCA-deficient ovarian cancers. According to the company, the trial design reflects evidence from earlier studies showing that immune priming with targeted cytotoxic therapy using a PARP inhibitor might sensitize ovarian tumors to added immune therapy.

According to Personalis, the ImmunoID NeXT system provides broad interrogation of both DNA and RNA across approximately 20,000 genes to identify biomarker signals associated with a variety of biologic features, including tumor escape mechanisms, immune repertoire profiles, neoantigen load, tumor mutational burden, microsatellite instability, oncoviruses, and immune checkpoint gene expression.

Financial terms of the study partnership with UNM were not disclosed.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.